These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25614856)

  • 1. Assessment of the Relationship between Galectin-3 and Ejection Fraction and Functional Capacity in the Patients with Compensated Systolic Heart Failure.
    Atabakhshian R; Kazerouni F; Raygan F; Amirrasouli H; Rahimipour A; Shakeri N
    Int Cardiovasc Res J; 2014 Dec; 8(4):143-7. PubMed ID: 25614856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of the prognostic value of galectin-3 in heart failure focusing on clinical utility of repeated testing.
    Carrasco-Sánchez FJ; Páez-Rubio MI
    Mol Diagn Ther; 2014 Dec; 18(6):599-604. PubMed ID: 24989720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.
    Lin YH; Lin LY; Wu YW; Chien KL; Lee CM; Hsu RB; Chao CL; Wang SS; Hsein YC; Liao LC; Ho YL; Chen MF
    Clin Chim Acta; 2009 Nov; 409(1-2):96-9. PubMed ID: 19747906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction.
    Polat V; Bozcali E; Uygun T; Opan S; Karakaya O
    Acta Cardiol; 2016 Apr; 71(2):191-7. PubMed ID: 27090041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher galectin-3 levels are independently associated with lower anxiety in patients with risk factors for heart failure.
    Sadlonova M; Meyer T; Binder L; Wachter R; Edelmann F; Herrmann-Lingen C
    Biopsychosoc Med; 2020; 14():24. PubMed ID: 33024450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Galectin-3 as a Novel Diagnostic Biomarker in Patients with Heart Failure with Preserved Ejection Fraction.
    Kanukurti J; Mohammed N; Sreedevi NN; Khan SA; Baba KSSS; Bhaskar MV; Satish OS; Naushad SM; Mohan IK
    J Lab Physicians; 2020 Aug; 12(2):126-132. PubMed ID: 32905127
    [No Abstract]   [Full Text] [Related]  

  • 7. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction.
    Sharma UC; Pokharel S; van Brakel TJ; van Berlo JH; Cleutjens JP; Schroen B; André S; Crijns HJ; Gabius HJ; Maessen J; Pinto YM
    Circulation; 2004 Nov; 110(19):3121-8. PubMed ID: 15520318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal function largely influences Galectin-3 prognostic value in heart failure.
    Zamora E; Lupón J; de Antonio M; Galán A; Domingo M; Urrutia A; Troya M; Bayes-Genis A
    Int J Cardiol; 2014 Nov; 177(1):171-7. PubMed ID: 25499371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galectin-3 as a Biomarker to Predict Cardiorenal Syndrome in Patients with Acute Heart Failure.
    Ozyildirim S; Dogan O; Barman HA; Tanyolaç S; Atıcı A; Enar R; Doğan SM
    Acta Cardiol Sin; 2023 Nov; 39(6):862-870. PubMed ID: 38022413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levels of Galectin-3 in Chronic Heart Failure: A Case-Control Study.
    Khadeja Bi A; Santhosh V; Sigamani K
    Cureus; 2022 Aug; 14(8):e28310. PubMed ID: 36158385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional and hemodynamic cardiac determinants of exercise capacity in patients with systolic heart failure.
    Hummel YM; Bugatti S; Damman K; Willemsen S; Hartog JW; Metra M; Sipkens JS; van Veldhuisen DJ; Voors AA
    Am J Cardiol; 2012 Nov; 110(9):1336-41. PubMed ID: 22818784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure.
    Di Salvo TG; Mathier M; Semigran MJ; Dec GW
    J Am Coll Cardiol; 1995 Apr; 25(5):1143-53. PubMed ID: 7897128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Value of Serum Concentration of Galectin-3 in Patients With Heart Failure With Preserved Ejection Fraction.
    Jiang J; Yang B; Sun Y; Jin J; Zhao Z; Chen S
    Front Cardiovasc Med; 2021; 8():829151. PubMed ID: 35141299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience.
    Sygitowicz G; Tomaniak M; Filipiak KJ; Kołtowski Ł; Sitkiewicz D
    Adv Clin Exp Med; 2016; 25(4):617-23. PubMed ID: 27629834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galectin-3 in heart failure with preserved ejection fraction.
    de Boer RA; Edelmann F; Cohen-Solal A; Mamas MA; Maisel A; Pieske B
    Eur J Heart Fail; 2013 Oct; 15(10):1095-101. PubMed ID: 23650131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional Status, Pulmonary Artery Pressure, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction.
    Dalos D; Mascherbauer J; Zotter-Tufaro C; Duca F; Kammerlander AA; Aschauer S; Bonderman D
    J Am Coll Cardiol; 2016 Jul; 68(2):189-99. PubMed ID: 27386773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mild systolic dysfunction in heart failure (left ventricular ejection fraction >35%): baseline characteristics, prognosis and response to therapy in the Vasodilator in Heart Failure Trials (V-HeFT).
    Carson P; Johnson G; Fletcher R; Cohn J
    J Am Coll Cardiol; 1996 Mar; 27(3):642-9. PubMed ID: 8606276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Assessment of left ventricular volume and functions by real-time three-dimensional echocardiography in patients with compensated and decompensated heart failure].
    Aktürk E; Kurtoğlu E; Ermiş N; Yağmur J; Açıkgöz N; Karakuş Y; Pekdemir H; Ozdemir R
    Turk Kardiyol Dern Ars; 2012 Sep; 40(5):419-26. PubMed ID: 23187435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of BNP and NT-proBNP in Patients With Heart Failure and Reduced Ejection Fraction.
    Rørth R; Jhund PS; Yilmaz MB; Kristensen SL; Welsh P; Desai AS; Køber L; Prescott MF; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
    Circ Heart Fail; 2020 Feb; 13(2):e006541. PubMed ID: 32065760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes.
    Nadruz W; West E; Santos M; Skali H; Groarke JD; Forman DE; Shah AM
    Circ Heart Fail; 2016 Apr; 9(4):e002826. PubMed ID: 27009553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.